Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview
出版年份 2020 全文链接
标题
Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 14, Pages 4919
出版商
MDPI AG
发表日期
2020-07-14
DOI
10.3390/ijms21144919
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Mechanisms of Multidrug Resistance in Cancer Chemotherapy
- (2020) Karol Bukowski et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study
- (2020) Angélique Vienot et al. World Journal of Gastrointestinal Oncology
- Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives
- (2019) Wonhee Woo et al. OncoTargets and Therapy
- One-step mechanochemical preparation and prominent antitumor activity of SN-38 self-micelle solid dispersion
- (2019) Xuanrong Sun et al. International Journal of Nanomedicine
- NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors
- (2019) Andrea Wang-Gillam et al. EUROPEAN JOURNAL OF CANCER
- A novel mechanism of irinotecan targeting MDM2 and Bcl-xL
- (2019) Boah Lee et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- BR2 and CyLoP1 enhance in-vivo SN38 delivery using pegylated PAMAM dendrimers
- (2019) Asma Mahmoudi et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells
- (2019) Damien Reita et al. Cancers
- UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysis
- (2018) Yuwei Yang et al. Asia-Pacific Journal of Clinical Oncology
- SN-38 Conjugated Gold Nanoparticles Activated by Ewing Sarcoma Specific mRNAs Exhibit In Vitro and In Vivo Efficacy
- (2018) Jordan A. Naumann et al. BIOCONJUGATE CHEMISTRY
- Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer
- (2018) Hanna K. Sanoff et al. CANCER
- Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer
- (2018) Chen Shaojun et al. CANCER BIOLOGY & THERAPY
- Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
- (2018) Femke M. de Man et al. CLINICAL PHARMACOKINETICS
- Functionalized graphene oxides for drug loading, release and delivery of poorly water soluble anticancer drug: A comparative study
- (2018) Neha Karki et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer
- (2018) Afroz S. Mohammad et al. PHARMACEUTICAL RESEARCH
- FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
- (2018) Caglayan Geredeli et al. World Journal of Surgical Oncology
- CD133-targeted delivery of self-assembled PEGylated carboxymethylcellulose-SN38 nanoparticles to colorectal cancer
- (2018) Mona Alibolandi et al. Artificial Cells Nanomedicine and Biotechnology
- Coadministration of cytotoxic chemotherapeutic agents with irinotecan is a risk factor for irinotecan-induced cholinergic syndrome in Japanese patients with cancer
- (2018) Ayako Tsuboya et al. International Journal of Clinical Oncology
- Radiosensitization by irinotecan is attributed to G2/M phase arrest, followed by enhanced apoptosis, probably through the ATM/Chk/Cdc25C/Cdc2 pathway in p53-mutant colorectal cancer cells
- (2018) Yaqi Wang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients
- (2018) Xun Bao et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Liposomal Irinotecan Achieves Significant Survival and Tumor Burden Control in a Triple Negative Breast Cancer Model of Spontaneous Metastasis
- (2018) Nicholas Bernards et al. MOLECULAR PHARMACEUTICS
- Drug resistance and new therapies in colorectal cancer
- (2018) Kevin Van der Jeught et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study
- (2018) Chan Wu et al. International Journal of Nanomedicine
- Irinotecan toxicity during treatment of metastatic colorectal cancer: focus on pharmacogenomics and personalized medicine
- (2018) Adam Paulík et al. TUMORI
- Self-assembled polypeptide nanoparticles for intracellular irinotecan delivery
- (2017) N.N. Zashikhina et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer
- (2017) Akitaka Makiyama et al. Gastric Cancer
- Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer
- (2017) Fernanda Musa et al. GYNECOLOGIC ONCOLOGY
- Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review
- (2017) Dorte Lisbet Nielsen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer
- (2017) Muhammad Alamgeer et al. INVESTIGATIONAL NEW DRUGS
- Type I DNA Topoisomerases
- (2017) Giovanni Capranico et al. JOURNAL OF MEDICINAL CHEMISTRY
- A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma
- (2017) Lei Wang et al. MEDICINE
- Type IA topoisomerases can be “magicians” for both DNA and RNA in all domains of life
- (2017) Muzammil Ahmad et al. RNA Biology
- Systemic Therapy for Small Cell Lung Cancer
- (2017) Benjamin Levy et al. Journal of the National Comprehensive Cancer Network
- Roles of eukaryotic topoisomerases in transcription, replication and genomic stability
- (2016) Yves Pommier et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia
- (2016) M Li et al. PHARMACOGENOMICS JOURNAL
- Tunable self-assembly of Irinotecan-fatty acid prodrugs with increased cytotoxicity to cancer cells
- (2016) Chunqiu Zhang et al. Journal of Materials Chemistry B
- Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine
- (2016) Shabbir Ahmed et al. GENOMICS PROTEOMICS & BIOINFORMATICS
- Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells
- (2015) Hai Wang et al. BIOMATERIALS
- Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis
- (2015) Xue-Qin Yang et al. BMC CANCER
- FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9 – FFCD 0802)
- (2015) Thomas Aparicio et al. DIGESTIVE AND LIVER DISEASE
- Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
- (2015) Edgar Pérez-Herrero et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
- (2015) Ken-ichi Fujita WORLD JOURNAL OF GASTROENTEROLOGY
- Akt inhibition improves irinotecan treatment and prevents cell emergence by switching the senescence response to apoptosis
- (2015) Alexandra Vétillard et al. Oncotarget
- Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial
- (2015) Yuankai Shi et al. Thoracic Cancer
- A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer
- (2014) Jaafar Bennouna et al. INVESTIGATIONAL NEW DRUGS
- A New-Class Antibacterial—Almost. Lessons in Drug Discovery and Development: A Critical Analysis of More than 50 Years of Effort toward ATPase Inhibitors of DNA Gyrase and Topoisomerase IV
- (2014) Gregory S. Bisacchi et al. ACS Infectious Diseases
- International Transporter Consortium Commentary on Clinically Important Transporter Polymorphisms
- (2013) K M Giacomini et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial
- (2013) Alfredo Carrato et al. JOURNAL OF CLINICAL ONCOLOGY
- Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study
- (2013) Kaoru Kubota et al. LANCET ONCOLOGY
- The role of p38 in irinotecan-induced DNA damage and apoptosis of colon cancer cells
- (2013) E. Rudolf et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
- Biomarker-Guided Repurposing of Chemotherapeutic Drugs for Cancer Therapy: A Novel Strategy in Drug Development
- (2013) Jan Stenvang et al. Frontiers in Oncology
- Drugging Topoisomerases: Lessons and Challenges
- (2012) Yves Pommier ACS Chemical Biology
- Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles
- (2012) Pedro M Valencia et al. Nanomedicine
- A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer
- (2012) J-Y Han et al. PHARMACOGENOMICS JOURNAL
- Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets
- (2011) D C Gilbert et al. BRITISH JOURNAL OF CANCER
- Conversion Chemotherapy Using Cetuximab plus FOLFIRI Followed by Bevacizumab plus mFOLFOX6 in Patients with Unresectable Liver Metastases from Colorectal Cancer
- (2011) K. Uehara et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- New Topoisomerase I mutations are associated with resistance to camptothecin
- (2011) Céline Gongora et al. Molecular Cancer
- Analysis of anticancer drugs: A review
- (2011) Susanne Nussbaumer et al. TALANTA
- Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer
- (2010) Suresh S. Ramalingam et al. CANCER
- Targeting the p38 MAPK Pathway Inhibits Irinotecan Resistance in Colon Adenocarcinoma
- (2010) S. Paillas et al. CANCER RESEARCH
- Genotoxic effects of irinotecan combined with the novel platinum(II) complexes in human cancer cells
- (2010) Renata Kontek et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Tyrosine Kinase Inhibitors
- (2010) C. Natoli et al. CURRENT CANCER DRUG TARGETS
- Proteomic analysis of cell lines to identify the irinotecan resistance proteins
- (2010) Xing-Chen Peng et al. JOURNAL OF BIOSCIENCES
- The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38
- (2009) Melissa J. LaBonte et al. INTERNATIONAL JOURNAL OF CANCER
- Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics
- (2009) Federico Innocenti et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124
- (2009) Primo N. Lara et al. JOURNAL OF CLINICAL ONCOLOGY
- Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management
- (2009) Alexander Stein et al. Therapeutic Advances in Medical Oncology
- Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial
- (2008) Michael S. Braun et al. JOURNAL OF CLINICAL ONCOLOGY
- Structural studies of type I topoisomerases
- (2008) N. M. Baker et al. NUCLEIC ACIDS RESEARCH
- Next generation topoisomerase I inhibitors: Rationale and biomarker strategies
- (2007) Beverly A. Teicher BIOCHEMICAL PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started